This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $615,621 to Powell Mansfield, Inc. to develop and validate a diagnostic tool for obstructive sleep apnea (OSA) called deep learning-enhanced transmembranous electromyography (DL-TMEMG).
The project aims to establish the feasibility of TMEMG to accurately diagnose OSA patients, optimize the deep learning algorithm, and then demonstrate...
This $128,047 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the development of an innovative urine-based diagnostic test for obstructive sleep apnea (OSA). The grant recipient, PGXL Technologies LLC, is collaborating with the University of Louisville Research Foundation to create a urine collection kit and validate a multiplex immunoassay panel using four protein biomarkers to detect...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) is for the development and use of a novel wearable sensor system called "Sleeptronix" to assess sleep, temperature, and cortisol levels in individuals with obstructive sleep apnea (OSA). The $253,500 award will be used to refine the Sleeptronix system and evaluate its ability to accurately measure clinically-used metrics like...
This Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $426,717 to The University of Iowa to develop a novel 3D dynamic MRI (3D-DMRI) scheme to quantify airway collapse in patients with obstructive sleep apnea (OSA). The goal is to create an alternative to the current standard drug-induced sleep endoscopy (DISE) procedure, which has several limitations, in order to better characterize the...
This $1,415,112 Project Grant, awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), aims to evaluate a telehealth-delivered adaptive intervention to promote continuous positive airway pressure (CPAP) therapy adherence and improve health outcomes for adults newly diagnosed with obstructive sleep apnea (OSA). The key objectives are to: 1) compare the effects of motivational enhancement, device support, and standard...
This Project Grant award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) aims to assess night-to-night variability in novel metrics for sleep-disordered breathing severity and their impact on daytime functioning. The $100,541 award to the University of Pittsburgh will leverage cutting-edge sleep monitoring technology and ecological momentary assessments to evaluate sex and gender differences in the relationship between sleep-disordered...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to develop an "RMT Complete" device and mobile application for respiratory muscle training. The $333,810 award to Novis Products, LLC will fund a Phase I study to assess the usability of the RMT Complete, which combines features such as an integrated manometer, resistance training, real-time biofeedback, and adherence tracking...
This $1,420,164 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to simultaneously evaluate changes in cerebral oxygen metabolism and upper airway anatomy in obstructive sleep apnea (OSA) patients. The key objectives are to: 1) optimize a time-resolved MRI protocol and synchronized airway plethysmography to detect metabolic and structural changes during induced apneas; 2)...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI)'s Cardiovascular Diseases Research program (CFDA 93.837) provides $301,224 to PGXL Technologies LLC, a minority-owned for-profit company, to advance the development of a urine-based, multiplex immunoassay for screening children for obstructive sleep apnea (OSA).
The project aims to integrate assays for four specific biomarkers (urocortin-3, kallikrein-1, orosomucoid-1, and uromodulin) into a panel that...
This $688,800 federal Project Grant was awarded on September 15, 2024 by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant will fund a 5-year research study at the University of Chicago to investigate the impact of obstructive sleep apnea (OSA) on glycemic control in adults with type 1 diabetes. The study aims to determine how OSA contributes to suboptimal...